Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Autologous Humanized Anti-CD22 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children

NCT04340167 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT04340167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04340167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Autologous Humanized Anti-CD22 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children
Lead sponsor
Beijing Boren Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2020
Completion date
April 3, 2024
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia, in relapse, refractory acute lymphoblastic leukemia